International Session（Symposium）3(JSGE・JGES・JSGS・JSGCS)
Thu. November 5th   14:00 - 17:00   Room 11: Portopia Hotel South Wing Topaz
IS-S3-3_G
 Current situation of IBD therapeutics in Taiwan
Shu Chen Wei1,2
1Department of Internal Medicine, National Taiwan University Hospital, 2Department of Internal Medicine, National Taiwan University College of Medicine
The global incidence and prevalence of inflammatory bowel disease (IBD) has increased over the last 2-4 decades, likely because of the adoption of a more “western” lifestyle as well as improved detection and awareness, and Taiwan is no exception. We updated the incidence and prevalence of IBD by analyzing data recorded from January 2001 through December 2015 in the registered database compiled by the National Health Insurance and provided by the Ministry of Health and Welfare, Taiwan. The crude incidence of CD increased from 0.17/100,000 in 2001 to 0.47/100,000 in 2015, whereas that of UC increased from 0.54/100,000 in 2001 to 0.95/100,000 in 2015. The prevalence of CD increased from 0.6/100,000 in 2001 to 3.9/100,000 in 2015, whereas that of UC increased from 2.1/100,000 in 2001 to 12.8/100,000 in 2015. The male-to-female ratio in the study sample was 2.19 for CD and 1.62 for UC. The median age of those registered with CD was lower than that of those registered for UC: 38.86 and 44.86 years, respectively.
With the increasing of disease awareness, we have less under-diagnosis cases, but we started to face the over- and mis-diagnosis situation. We felt that correct diagnosis is extremely important, therefore, Taiwan Society of IBD invited the experts to pool their experience and published the “Case Studies and Endoscopic Images in IBD and its Mimics” to assist the younger generation of gastroenterologists to rapidly gain virtual experience in reading and differentiating ulcerative lesions seen by colonoscopy.
Taiwan probably is the very rare country that have the adalimumab years ahead of the infliximab. Currently, we have all the available biologics (infliximab, infliximab biosimilar, adalimumab, golimumab, vedolizumab, ustekinumab) and small molecule (tofacitinib), in addition to the conventional therapy for IBD. However, there’s limited period of reimbursement (currently as one year) of biologics, which made the treatment for IBD as a big challenge both for the doctors as well as for the patients. Nonetheless, with the education, we are happy to see the mortality of IBD patients has decreased significantly in Taiwan recently.
Index Term 1: IBD
Index Term 2: Taiwan
Page Top